Name: NEUROGENE INC (NGNE) Stock
Brand: NEUROGENE INC
Rating: 4 (3 reviews)

NGNE Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Neurogene Inc.

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

19 days ago - By: Neurogene Inc.

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

25 days ago - By: Neurogene Inc.

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

26 days ago - By: Neurogene Inc.

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Benzinga - Mentions: QURE RCKT CABA KYTX

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

2 months ago - By: Benzinga - Mentions: XTLB NXL GTBP PCSA ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: Neurogene Inc.

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

2 months ago - By: Neurogene Inc.

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

2 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Neurogene Inc.

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

4 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Neurogene Inc.

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

6 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Yahoo Finance - Mentions: DNUT MDGL FLWS RKT

Short Report: Bears bite into Krispy Kreme after another weak earnings report

7 months ago - By: Neurogene Inc.

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

7 months ago - By: Neurogene Inc.

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

7 months ago - By: Neurogene Inc.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Neurogene Inc.

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

8 months ago - By: Neurogene Inc.

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

8 months ago - By: Neurogene Inc.

NEUROGENE INC (NGNE) Stock News

NGNE Latest News, Press Relases and Analysis

Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates

Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

12 Health Care Stocks Moving In Thursday's Intraday Session

Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Short Report: Bears bite into Krispy Kreme after another weak earnings report

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates